Drug intelligence / Profile preview

JCXH-301

Development stage: Preclinical
Lead developer: Immorna
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous, Other Parenteral Routes Likely But Not Explicitly Stated

Overview

JCXH-301 is an enzyme replacement drug developed by Jiachen Xihai (Hangzhou) Biotechnology Co., Ltd. It is primarily indicated for the treatment of Gaucher Disease, a genetic disorder caused by deficiency of the enzyme glucocerebrosidase. The drug functions as an enzyme replacement therapy to compensate for the deficient or malfunctioning enzyme in patients with this congenital metabolic disorder. Currently, JCXH-301 is in preclinical development stages and has not yet reached clinical trials or approval status. The development focuses on nervous system diseases, congenital disorders, and endocrinology/metabolic diseases related to Gaucher Disease[1][3].

Other names: JCXH-301JCXH301JCXH 301

Targets

GBA1 (Glucosylceramidase)

Beyond the preview

Go deeper on JCXH-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JCXH-301.

Explore the full profile